Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 May 24;11:10765. doi: 10.1038/s41598-021-90143-4

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Abiraterone induces overexpression of lt-SLCO1B3 while suppressing hsa-miR-579-5p expression. Effects of abiraterone treatment on the expression of (a) lt-SLCO1B3 and (b) hsa-miR-579-3p in the samples processed for NanoString analysis were validated by qPCR analysis. As expected hsa-miR-579-3p expression was reduced and lt-SLCO1B3 expression was increased following abiraterone treatment, consistent with miRNA-transcript repression. (c) hsa-miR-579-3p directly binds to SLCO1B3 3′UTR. Co-transfection of 22Rv1 cells was performed with the 3′UTR reporter plasmid (or vector control plasmid) and hsa-miR-579-3p mimic (or negative control mimic) for 24 h followed by luciferase reporter assays. The assay revealed a significant decrease in SLCO1B3 reporter activity in the presence of the mimic. 22Rv1 cells were also transfected with the 3′UTR plasmid (or vector control plasmid) followed by treatment with 20 µM Abiraterone (or vehicle DMSO control) for 24 h. Abiraterone treatment resulted in an increase in SLCO1B3 luciferase reporter activity. No significant change was observed in the vector control plasmid lacking the 3′UTR (see Supplementary Fig. S4). These data are the results of three independent experiments performed in triplicates. ***P < 0.005, ****P < 0.0001.